GenprotX
GenprotX is a biotechnology company based in Oslo, Norway, dedicated to advancing early target discovery for precision therapeutics in cancer care and drug discovery for pancreatitis. They focus on reducing screen-to-hit time, identifying high-value actionable targets, and developing innovative solutions for cancer and inflammatory diseases. Their multidisciplinary team leverages molecular biology, immunology, and AI-driven screening to push boundaries in treatment options.
Industries
Nr. of Employees
small (1-50)
Products
Preclinical-stage drug candidates for pancreatitis
Proprietary preclinical drug candidates demonstrating efficacy in in vivo models of acute and chronic pancreatitis intended for further development or partnership.
Preclinical-stage drug candidates for pancreatitis
Proprietary preclinical drug candidates demonstrating efficacy in in vivo models of acute and chronic pancreatitis intended for further development or partnership.
Services
Research support services for acute and chronic pancreatitis including biomarker discovery, immune profiling, and target identification.
Multi-modal R&D acceleration services to support target discovery and optimization for pancreatic oncology therapeutics and preclinical-to-clinical transition.
Target discovery and hit identification services focused on small molecule and peptide modalities, with processes designed to reduce screen-to-hit timelines.
Analytical and discovery services to identify biomarkers and characterize immune responses relevant to pancreatic diseases.
Execution of in vivo pharmacology studies in pancreatitis models to demonstrate candidate efficacy prior to clinical progression.
Research support services for acute and chronic pancreatitis including biomarker discovery, immune profiling, and target identification.
Multi-modal R&D acceleration services to support target discovery and optimization for pancreatic oncology therapeutics and preclinical-to-clinical transition.
Target discovery and hit identification services focused on small molecule and peptide modalities, with processes designed to reduce screen-to-hit timelines.
Analytical and discovery services to identify biomarkers and characterize immune responses relevant to pancreatic diseases.
Execution of in vivo pharmacology studies in pancreatitis models to demonstrate candidate efficacy prior to clinical progression.
Expertise Areas
- Early target discovery
- Pancreatitis drug discovery
- Pancreatic cancer research and therapeutics
- Biomarker discovery
Key Technologies
- Multi-omics (integrated genomics/proteomics/etc.)
- AI-driven screening algorithms
- In vivo preclinical disease models
- Immune profiling assays